2024/04/25 18:21:08 | |
---|---|
Price | |
0.4408 USD | |
Difference | -4.38% (-0.02) |
ISIN | NL0014040206 |
Symbol | CNTG |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 12 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | 0.4408 USD (1,000) |
Ask (Ask size) | 0.4591 USD (100) |
Open | 0.45 USD |
High | 0.45 USD |
Low | 0.4408 USD |
Close (prev. day) | 0.461 USD |
VWAP | 0.448736 USD |
Volume (pcs) | 5,811 |
Trading volume | 2,608.12 |
Number of trades | 28 |
Last size | 100 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/04/03 | Global Equity Ratings | ||
2024/03/13 | Global Equity Ratings | ||
2024/02/22 | Global Equity Ratings | ||
2024/02/14 | Global Equity Ratings | ||
2024/01/23 | Global Equity Ratings |
2024/04/25 18:21:08 | |
---|---|
Price | |
0.4408 USD | |
Difference | -4.38% (-0.02) |
ISIN | NL0014040206 |
Symbol | CNTG |
Exchange | Nasdaq |
Currency | USD |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 12 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | 0.4408 USD (1,000) |
Ask (Ask size) | 0.4591 USD (100) |
Open | 0.45 USD |
High | 0.45 USD |
Low | 0.4408 USD |
Close (prev. day) | 0.461 USD |
VWAP | 0.448736 USD |
Volume (pcs) | 5,811 |
Trading volume | 2,608.12 |
Number of trades | 28 |
Last size | 100 |
6m | 1Y | 3Y | |
Perf (%) | -56.92% | -37.70% | -95.73% |
Perf (abs.) | -0.61 | -0.28 | -10.34 |
Beta | 0.56 | 0.91 | 0.69 |
Volatility | 91.02 | 106.45 | 100.01 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.4656 USD (125,813) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.6227 USD (97,712) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.9363 USD (43,093) |
Ø price 250 days | Ø volume 250 days (pcs.) | 1.0099 USD (312,016) |
YTD High | date | 1.2500 USD (2024/01/16) |
YTD Low | date | 0.4310 USD (2024/04/19) |
52 Weeks High | date | 2.5200 USD (2023/04/25) |
52 Weeks Low | date | 0.4310 USD (2024/04/19) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Tradegate | 2024/04/25 | 17:20 | 0.435 EUR | 0.00 | 2 |
Stuttgart | 2024/04/25 | 18:44 | 0.382 EUR | 0.00 | 3 |
Nasdaq | 2024/04/25 | 18:21 | 0.4408 USD | 0.00 | 28 |
Munich | 2024/04/25 | 08:11 | 0.444 EUR | 0.00 | 1 |
Hamburg | 2024/04/25 | 08:16 | 0.3885 EUR | 0.00 | 1 |
Frankfurt | 2024/04/25 | 14:29 | 0.3885 EUR | 0.00 | 2 |
Duesseldorf | 2024/04/25 | 16:30 | 0.4175 EUR | 0.00 | 4 |
Berlin | 2024/04/25 | 18:43 | 0.42 EUR | 0.00 | 15 |
CENTOGENE NV |
- - |
Am Strande 7 - 18055 Rostock |
Telefon: +49-381-80113400 |
Fax: +381-80113401 |
E-mail: - |
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark. |
Kim Stratton | Chairman of Managing Board |
Bettina Goerner | Member of Executive Committee |
Ian Rentsch | Member of Executive Committee |
Miguel Coego Rios | Member of Executive Committee |
Patrice P. Denèfle | Member of Executive Committee |
Peter Bauer | Member of Executive Committee |
Peer Schatz | Chairman of Supervisory Board |
Eric Souêtre | Member of Supervisory Board |
Flemming Ørnskov | Member of Supervisory Board |
Hubert Birner | Member of Supervisory Board |
Jonathan Sheldon | Member of Supervisory Board |
Guido Prehn | Member of Supervisory Board |
Mary Sheahan | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer